SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing extreme volatility driven by a massive, supply-constrained short squeeze that has captivated the trading community. Investors are actively debating whether this parabolic move is a sustained mechanical phenomenon controlled by major stakeholders or a high-risk bubble nearing an inevitable and violent exhaustion.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to CFO Thomas Mikas comments confirming production orders from hyperscalers and key partnerships that validate the company's optical engine technology. The community is actively dismissing recent short-seller reports and expressing high conviction, with sentiment bolstered by bullish option activity and excitement over the potential for the stock to scale alongside the AI infrastructure buildout.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing intense volatility and social media attention as traders debate whether its recent surge is a sustainable breakout driven by its role in AI data center power infrastructure or a speculative bubble destined for a reversal. The community remains sharply divided, with bulls pointing to the company's strategic partnerships and GaN technology advancements, while bears argue the valuation is detached from current revenue and profitability.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is surging after reporting positive registrational trial data for its CAR-T therapy, miv-cel, in treating Stiff Person Syndrome, showing statistically significant improvements in mobility and independence. The community is actively discussing the stock's potential for FDA approval by early 2026, comparing its efficacy against competitors, and speculating on its status as a prime acquisition target for larger pharmaceutical firms.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are intensely debating whether the semiconductor sector is currently in a historic blow-off top or a sustained rally, with many expressing frustration over the persistent daily declines in this inverse ETF despite sector volatility. The community is deeply divided between those capitulating on their positions due to extreme exhaustion and those aggressively averaging down, pinning their hopes on an impending earnings-driven market correction or a significant technical reversal.

OpenGradient

OpenGradient is gaining significant momentum as investors rotate capital from other speculative assets, with the community actively highlighting its early-stage potential and high-volume trading activity.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch is capturing attention as the community rallies around its unique passive income model, which automatically distributes Solana rewards to holders every six hours. Investors are actively discussing the project's resilience, recent technical developments, and the long-term utility of its reward-generating mechanism.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is at the center of a polarizing debate as investors weigh significant long-term potential in the eVTOL sector against immediate frustrations regarding the lack of a piloted transition flight. While community members are hotly debating the company's technical progress, regulatory hurdles, and speculative partnerships, the stock remains a focal point for active trading as participants react to ongoing news cycles and market-wide volatility.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing significant volatility driven by high short interest and social media buzz comparing its setup to previous retail-led short squeezes. The community remains deeply divided, with bulls pointing to the company's turnaround efforts and asset holdings, while bears emphasize concerns over weak fundamentals, potential overvaluation, and concerns regarding market manipulation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares (SOXL) is experiencing extreme volatility and a parabolic rally driven by intense speculative momentum and persistent short-covering as the semiconductor sector continues to reach new highs. The community is sharply divided, with bulls celebrating life-changing gains and betting on further upside, while bears warn of a speculative bubble, significant leverage decay, and the high risks associated with holding a 3x leveraged product in an overextended market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks Research

Zacks Research lowered shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Thursday...

HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Sangamo Therapeutics in a research note issued...

Equities Analysts Issue Forecasts for SGMO FY2028 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright reduced their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Thursday, April...

<ul class="summary-bullets"><li>PEPG fell after its Phase 2 Freedom 2 study showed no meaningful improvements in walking speed or hand strength at the starting dose of 5 mg/kg.</li><li>SGMO slipped after reporting a Q4 loss per share of $0.11 versus the expected loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.</li><li>PHR declined after cutting its FY27 revenue outlook to $510 million-$520 million from $545 million-$559 million, below analyst expectations of $552.1 million.</li></ul>Shares of PepGen (PEPG), Sangamo Therapeutics (SGMO), and Phreesia (PHR) were among the top premarket losers on Tuesday as investors reacted to muted functional trial results, a wider-than-expected loss, and a revenue outlook cut, prompting analyst downgrades.In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%.<h2 class="st-heading-2">PepGen Trial Shows No Functional Gains At Low Dose</h2>PepGen reported results from the lowest-dose cohort in its Phase 2 Freedom 2 study of PGN-EDODM1 in patients with myotonic dystrophy type 1, with investors focusing on the lack of functional improvement at the starting dose.The company said the therapy was generally well tolerated, with all adverse events mild or moderate and no serious adverse events reported. However, the company also said patients showed “no meaningful improvements” in walking speed or hand strength at the starting 5 mg/kg dose of PGN-EDODM1.PepGen said patients receiving the treatment showed an average 7.3% improvement on a disease-related molecular metric, compared with 6.8% in placebo patients, rising to 22.9% after excluding one outlier. The company expects results from the higher 10 mg/kg cohort in the second half of 2026, with cash expected to support operations into the second half of 2027.<h2 class="st-heading-2">Sangamo Loss Widens As Funding Outlook Weighs</h2>Sangamo Therapeutics reported a fourth-quarter (Q4) loss per share of $0.11, wider than analyst expectations for a loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.The company highlighted progress in its Fabry disease gene therapy program, saying it is “well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway” following positive topline results from the registrational STAAR study.However, sentiment appeared pressured after the company said its 2026 expense outlook is “subject to our ability to secure adequate additional funding for our current operating plan.” Sangamo expects non-GAAP operating expenses of $110 million to $120 million in 2026.<h2 class="st-heading-2">Phreesia Guidance Cut Triggers Broker Downgrades</h2>Phreesia reported Q4 revenue of $127.1 million, slightly above analyst expectations of $126.6 million, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose to $29.4 million from $16.4 million a year earlier.Shares fell after the company lowered its fiscal 2027 revenue outlook to $510 million to $520 million, down from $545 million to $559 million, and below analyst expectations of $552.1 million. The company said, “Network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December.”Following the guidance cut, Baird downgraded the stock to ‘Neutral’ from ‘Outperform’ and reduced its price target to $10 from $25, saying “the magnitude of the follow-on impact exceeded expectations.” Truist Securities also downgraded the stock to ‘Hold’ from ‘Buy’ and lowered its price target to $11 from $24, citing “the meaningful reduction to the revenue outlook.”<h2 class="st-heading-2">How Do Retail Traders Feel About PEPG, SGMO And PHR?</h2>On Stocktwits, retail sentiment for PEPG, SGMO and PHR was ‘extremely bullish’ amid ‘extremely high’ message volume.Over the past year, PEPG has risen 186%, while SGMO has fallen 63% and PHR has declined 56%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/unh-stock-below-buffett-entry-price-first-revenue-decline-30-years-ai/cZEPohoRINz">UNH Stock Slides Back Below Warren Buffett’s Entry Price As Annual Revenue Faces First Decline In 30 Years — AI May Be Long-Term Fix</a>

Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.  In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%

Equity

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.

Sangamo Therapeutics Q4 Earnings Call Highlights

Sangamo Therapeutics (NASDAQ:SGMO) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight progress across its Fabry disease and neurology pipelines, while...

Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) issued its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.12). Sangamo Therapeutics had a negative net margin of 331.28...

Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Sangamo Therapeutics will release Q4 earnings on March 30. Analysts predict a quarterly loss of 5 cents per share and revenue of $40.25 million.read more...

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +91.67% and -28.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates

Adherex Technologies (FENC) delivered earnings and revenue surprises of -540.00% and -7.94%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Current Price	$0.2575
Prev Close	$0.2701
Open	$0.27
Dividend Yield	0.00%
50-Day Moving Average	$0.3474
Beta	1.66
Avg. Volume	6.31M
PE Ratio	-0.58

52-Week High	$0.84
52-Week Low	$0.205
Market Capitalization	$111.9M
EPS (Annual)	-$0.4387
Price to Book	-6.33
Revenue Per Employee	$278,535.21

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMO News

SGMOSangamo Therapeutics Inc